To include your compound in the COVID-19 Resource Center, submit it here.

AnaptysBio shares double on atopic dermatitis data

AnaptysBio Inc. (NASDAQ:ANAB) gained $35.41 (101%) to $70.41 on Tuesday after reporting data from a Phase IIa trial of lead program ANB020,

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE